In fact, pioglitazone, DPP-4 inhibitors, GLP-1 agonists and acarbose, unlike insulin (22), could all have some beneficial effect on cardiovascular risk (44-47); furthermore, they do not induce hypoglycemia, which is negative cardiovascular mortality (48) and they require no regular blood glucose self-monitoring. This evidence concerns the gene INS and Hypoglycemia.